v3.25.4
Organization and Nature of Operations (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Oct. 31, 2024
Dec. 31, 2022
Organization and Nature of Operations [Line Items]                        
Net loss $ 31,252 $ (649,444) $ (540,943) $ (885,942) $ (364,191) $ (1,610,880) $ (1,159,135) $ (2,861,013) $ (3,016,884) $ (2,456,550)    
Net cash used in operations             (631,819) (523,983) (660,302) (647,860)    
Accumulated deficit (8,418,501)           (8,418,501)   (7,259,366) (4,242,482)    
Stockholders’ deficit (3,310,908) $ (3,402,160) $ (2,752,716) $ (2,329,074) $ (2,011,756) $ (1,647,565) (3,310,908) $ (2,329,074) (2,378,145) (1,461,565)   $ (826,167)
Working capital deficit 3,319,663           3,319,663   2,378,145      
Cash on hand $ 3,317           $ 3,317   $ 6,741 $ 7,263    
Precision Genomics, Inc. [Member]                        
Organization and Nature of Operations [Line Items]                        
Ownership percentage                     100.00%  
Exousia Ai, Inc.[Member]                        
Organization and Nature of Operations [Line Items]                        
Ownership percentage                 100.00%